[{"id":"2abe0645-3142-4734-8213-c40fc6f02c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05586074","created_at":"2022-10-19T13:56:29.070Z","updated_at":"2024-07-02T16:35:52.642Z","phase":"Phase 3","brief_title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","source_id_and_acronym":"NCT05586074","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • decitabine • idarubicin hydrochloride • fludarabine IV • clifutinib (HEC73543)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 02/10/2026","primary_completion_date":" 02/10/2026","study_txt":" Completion: 05/14/2026","study_completion_date":" 05/14/2026","last_update_posted":"2023-03-23"},{"id":"fc6da593-35d9-481a-b7d3-4ce975ca2fc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04827069","created_at":"2021-04-01T15:52:18.247Z","updated_at":"2024-07-02T16:36:05.589Z","phase":"Phase 1","brief_title":"A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)","source_id_and_acronym":"NCT04827069","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clifutinib (HEC73543)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/18/2018","start_date":" 05/18/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2022-08-12"},{"id":"e9daa2db-3604-457c-85f1-b68c2abf1b38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05133882","created_at":"2021-11-25T00:36:12.656Z","updated_at":"2024-07-02T16:36:10.848Z","phase":"Phase 1/2","brief_title":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","source_id_and_acronym":"NCT05133882","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • clifutinib (HEC73543)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 02/18/2025","primary_completion_date":" 02/18/2025","study_txt":" Completion: 10/07/2026","study_completion_date":" 10/07/2026","last_update_posted":"2022-05-06"}]